Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah K Knutson

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|January 16, 2016
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of TazemetostatKevin W Kuntz, John E Campbell, Heike Keilhack, et al.
Plos One|January 14, 2017
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Molecular Cancer Therapeutics|August 25, 2017
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCLDorothy Brach, Danielle Johnston-Blackwell, Allison Drew, et al.
Plos One|July 9, 2016
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Mobile DNA|November 22, 2023
Proceedings of the inaugural Dark Genome Symposium: November 2022Jef D Boeke, Kathleen H Burns, Katherine B Chiappinelli, et al.
Plos One|December 11, 2014
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K Knutson, Natalie M Warholic, L Danielle Johnston, et al.
Molecular Cancer Therapeutics|September 5, 2024
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in CancerRobinson Triboulet, Khikmet Sadykov, Darren M Harvey, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Cancer Cell|November 16, 2010
Hdac3 is essential for the maintenance of chromatin structure and genome stabilitySrividya Bhaskara, Sarah K Knutson, Guochun Jiang, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|January 16, 2016
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of TazemetostatKevin W Kuntz, John E Campbell, Heike Keilhack, et al.
Plos One|January 14, 2017
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Molecular Cancer Therapeutics|August 25, 2017
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCLDorothy Brach, Danielle Johnston-Blackwell, Allison Drew, et al.
Plos One|July 9, 2016
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Mobile DNA|November 22, 2023
Proceedings of the inaugural Dark Genome Symposium: November 2022Jef D Boeke, Kathleen H Burns, Katherine B Chiappinelli, et al.
Plos One|December 11, 2014
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K Knutson, Natalie M Warholic, L Danielle Johnston, et al.
Molecular Cancer Therapeutics|September 5, 2024
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in CancerRobinson Triboulet, Khikmet Sadykov, Darren M Harvey, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Cancer Cell|November 16, 2010
Hdac3 is essential for the maintenance of chromatin structure and genome stabilitySrividya Bhaskara, Sarah K Knutson, Guochun Jiang, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Pageof 3